Obesity is a major risk factor for the development of type 2 diabetes; [1] [2] [3] moreover, the presence of obesity in type 2 diabetes is associated with an increased risk of vascular complications associated with the disorder. 4, 5 The majority of patients are overweight or obese at diagnosis of type 2 diabetes. Recent clinical trials have demonstrated that progression to diabetes in obese patients with impaired glucose tolerance can be prevented through weight reduction and increased levels of physical activity. 6, 7 For patients who have developed type 2 diabetes, intentional weight loss has many potential benefits, including improved metabolic control and a reduced need for antidiabetic medications. [8] [9] [10] One of the challenges of using antidiabetic therapy in obese or overweight patients is the prospect of substantial iatrogenic weight gain with many widely used drug classes. Since lifestyle interventions, including weight loss, are usually very difficult to achieve and/or sustain, the practitioner frequently is left with few options when trying to avoid adverse effects of antidiabetic therapy that are counterproductive to efforts directed at weight loss. A new anti-obesity agent, the selective cannabinoid receptor antagonist rimonabant, is effective in reducing weight and improving a range of metabolic defects in patients with type 2 diabetes. Such new agents should improve our ability to treat overweight or obese patients.
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New classes of antidiabetic agents mimic or potentiate the activities of incretin hormones, including the injectable glucagon-like peptide-1 (GLP-1) mimetics and the oral dipeptidyl peptidase-4 (DPP- 4) inhibitors. These drugs have benefits for glucose-dependent insulin secretion, suppression of glucagon secretion, inhibition of gastric emptying and appetite reduction. [11] [12] [13] [14] They are effective in lowering glycated haemoglobin (HbA 1c ) and are associated with either weight loss (GLP-1 mimetics) or weight neutrality (oral DPP-4 inhibitors). Thus, these drugs promise to be useful in obese/overweight patients with type 2 diabetes.
A new anti-obesity agent, the selective cannabinoid receptor antagonist rimonabant, is effective in reducing weight and improving a range of metabolic defects in patients with type 2 diabetes. Such new agents should improve our ability to treat overweight or obese patients.
Effects of Traditional Oral Antidiabetic

Agents on Bodyweight
Insulin Secretagogues
Sulfonylureas
As insulin secretion is relatively deficient in type 2 diabetes, use of insulin secretagogues is logical for patients in whom the β-cell defect is not too advanced. Treatment with sulfonylureas (SUs) reduces HbA 1c by approximately 1-2%. SU treatment in the UK Prospective Diabetes Study (UKPDS) was associated with a significant reduction in microvascular complications and a trend towards reduction of myocardial infarction (MI), but no significant effect on diabetes-related or all-cause mortality. 15 Weight gain and hypoglycaemia -the latter usually asymptomatic or mild -are common side effects with these agents. [16] [17] [18] Longer-acting agents (e.g. chlorpropamide, glyburide (glibenclamide) and sustainedrelease glipizide) are more likely to cause hypoglycaemia than shorteracting agents. 18 Weight gain averages about 1-4kg and generally stabilises over six months. In the UKPDS, for example, weight gain was 1.7kg with glyburide and 2.6kg with chlorpropamide. Weight increases with SU treatment may be partly due to anabolic effects of increased plasma insulin levels or reduced loss of calories as glucose in the urine. 17 Lesser degrees of weight gain are claimed for some SU formulations (e.g. extended-release glipizide). 19 However, individual metabolic responses to these agents vary, and weight gain should be anticipated with any agents in this class. SUs are, therefore, widely regarded as being less attractive as first-line therapy for obese patients; however, they remain in widespread use, often in combination with other drugs, notably metformin. When used in obese patients, treatment with SUs should be accompanied by a weight control programme of diet and exercise wherever possible.
Rapid-acting Secretagogues
The non-sulfonylurea secretagogues repaglinide and nateglinide were developed to have a rapid onset and short metabolic half-life, resulting in preferential targeting of post-prandial hyperglycaemia. These agents reduce HbA 1c to a degree broadly similar to that observed with SUs (about 1-2%), with repaglinide having a somewhat greater effect in this regard. [16] [17] [18] The drugs must be taken before each main meal. As with other insulin secretagogues, hypoglycaemia and weight gain are the most common side effects, although both appear to be reduced in frequency compared with SUs. In a study involving 576 patients with type 2 diabetes, less weight gain was observed with repaglinide than with glyburide (2.5kg versus 3.6kg, respectively) among pharmacotherapy-naïve patientsalthough previously treated patients did not exhibit less weight gain with repaglinide. 20 In general, no weight loss can be expected in patients switched from an SU to repaglinide. Nateglinide is a D-phenylalanine derivative with a faster onset and shorter duration of action than 
Insulin Sensitisers
Thiazolidinediones
Thiazolidinediones (TZDs) act to increase insulin sensitivity in adipose tissue, muscle and the liver. 23 Rosiglitazone and pioglitazone reduce HbA 1c by about 0.5-1.5%. [16] [17] [18] However, these agents are associated with weight gain. A small proportion of patients develop leg oedema, which is attributed to fluid retention; heart failure is a concern in vulnerable patients (and is discussed below). Weight gain is generally similar to that seen with SUs (i.e. about 1-4kg, with stabilisation over six to 12 months). Of note, weight gain may be increased with concomitant treatment with other medications, including insulin. 24 The weight gain with TZDs is partly attributable to adipogenesis, but recent data suggest that fluid retention may in fact be the main cause. 25 There is some evidence that fat is redistributed away from visceral deposits, which are more closely associated with insulin resistance, to subcutaneous deposits. [16] [17] [18] TZDs have complex effects on atherogenic lipid profiles with some notable differences between the two agents. 26 In the secondary prevention PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) trial in highrisk patients with type 2 diabetes, pioglitazone was associated with a statistically significant 16% reduction in the secondary end-point of allcause mortality, non-fatal MI or stroke. However, an increased frequency of heart failure and oedema without heart failure, as well as a 4kg weight increase compared with placebo, detracted from the positive impact on vascular events. 27, 28 In the EU, TZDs are contraindicated in patients with a history of heart failure or current evidence of heart failure; their use in combination with insulin is contraindicated because of a perceived increased risk of heart failure. Recent US guidelines urge a cautious approach to TZD use in patients with evidence of heart failure. TZDs are also contraindicated in patients with active liver disease, although their effects on the liver are still under investigation; reduced levels of hepatic transaminases have been reported in several studies.
Metformin
Metformin, the only widely available biguanide, acts primarily by reducing hepatic glucose production and thereby reducing fasting hyperglycaemia in the presence of a sufficient amount of insulin. The drug improves postreceptor insulin signalling to increase cellular insulin sensitivity. 17, 29 Metformin does not stimulate insulin secretion and may decrease hyperinsulinemia, an action regarded as potentially beneficial in obese patients. The agent reduces HbA 1c by approximately 1-2%. 16, 17, 29 Metformin also results in small beneficial changes in the atherogenic lipid profile and may exert positive effects on other cardiovascular risk factors. 17 In the UKPDS, metformin therapy in obese patients (mean body mass index (BMI) approximately 32kg/m 2 ) randomised to the drug after an inadequate response to diet was associated with statistically significant reductions of 32% in any diabetes-related end-point, 39% in MI and 42% in diabetesrelated mortality. 30 In the Diabetes Prevention Program, metformin therapy reduced the risk of diabetes by 31% in obese patients with impaired glucose tolerance. 7 Metformin is not associated with weight gain and can sometimes promote modest weight loss. In the UKPDS, obese patients randomised to metformin gained 1-2kg compared with gains of 5-7kg in patients receiving SU or insulin treatment. 30 In the Diabetes Prevention
Program, metformin was associated with weight loss of 2.1kg. 7 Co-administration of metformin with insulin has the potential to reduce insulin-associated weight gain. 31 The mechanisms of weight neutrality or weight loss associated with metformin in this context are not completely understood. Suggestions include a reduction in hyperinsulinaemia, a reduced risk of hypoglycaemia and hence lower calorie consumption, or decreased food intake as a consequence of the well-recognised gastrointestinal (GI) side effects of the drug; these often include a degree of anorexia.
Overall, these characteristics of metformin make it a preferred therapy for obese patients with type 2 diabetes. Use of the drug is limited, however, by risk of lactic acidosis -a rare condition but one associated with a high case-fatality rate. For this reason, metformin is limited to patients with renal function sufficient to avoid drug accumulation and is contraindicated in patients with cardiac or respiratory insufficiency (e.g.
congestive heart failure (CHF)), other conditions associated with hypoxia or reduced perfusion, hepatic dysfunction, alcoholism or history of metabolic acidosis. [16] [17] [18] Use of metformin is also limited by the high frequency of GI adverse effects; a lesser proportion of patients cannot tolerate metformin at higher doses, whereas a minority are unable to tolerate the drug at any dose.
a-Glucosidase Inhibitors
The a-glucosidase inhibitors (AGIs) reduce the rate of polysaccharide digestion in the proximal small intestine, thereby reducing post-prandial DPP-4 Inhibition in Type 2 Diabetes Management hyperglycaemia, by inhibiting intestinal a-glucosidase enzymes. [16] [17] [18] These agents (acarbose, miglitol, voglibose) are taken three times daily with meals that contain digestible carbohydrates. 
Insulin
Insulin, the most effective glucose-lowering drug, is sometimes the treatment of choice in patients with type 2 diabetes and is often required when glycaemic goals cannot be obtained using oral agents. 33 However, the adverse effects of insulin often lead to suboptimal results in clinical practice. Most important from the perspective of the patient is the substantial weight gain, ranging from 2kg to nearly 10kg with various formulations, that so often accompanies insulin treatment. [34] [35] [36] [37] This weight gain poses particular problems for overweight or obese patients who usually have preexisting insulin resistance, weight-related health issues and longerterm health risks. Gains in bodyweight appear to increase in proportion to daily insulin dose and plasma insulin concentration. 24 The magnitude of weight gain may, to some extent, also reflect the timing of insulin injections, co-administration of oral antidiabetic agents and risk of hypoglycaemia. In fact, the risk of severe hypoglycaemia is relatively low in obese insulin-resistant patients treated with insulin in the early course of the disorder. 33 
New Antidiabetic Agents
The metformin/SU) to 2.5kg (when added to metformin) at the approved 5µg and 10µg doses in six-month studies. [39] [40] [41] In a relatively small group of overweight metformin-treated patients followed for 82 weeks, there was maintained reduction in HbA 1c and continued weight loss (5.3kg). 42 In a comparison with insulin glargine, both treatments reduced HbA 1c by 1.1%, and exenatide produced a 2.3kg weight loss compared with a weight gain of 1.8kg with insulin glargine. 43 Severe hypoglycaemia has been infrequent with use of exenatide, but hypoglycaemia occurred in 14-36% of patients receiving SU or metformin/SU; accordingly, a dose reduction in SU is recommended when the agents are combined. 44 In addition to its need for twice-daily injection, exenatide use may be limited by a high frequency of GI adverse events, including nausea and, less commonly, vomiting (see Table 1 ). A new long-acting formulation to be administered once weekly is in development that may offer substantially better prospects in terms of patient acceptability.
Liraglutide is an acylated GLP-1 mimetic in development that has a half-life long enough to permit once-daily subcutaneous dosing. In a recent 14-week study in obese patients, liraglutide once daily significantly reduced HbA 1c at doses of 0.65, 1.25 and 1.9mg (1.7% reduction at highest dose); liraglutide therapy was associated with dose-dependent reductions in bodyweight of 3.0kg at the highest dose compared with a loss of 1.2kg with placebo. 45 GI adverse effects were common but appeared to decrease over time. Modelling studies have indicated improved β-cell function during treatment with these agents. 11-13,53,54 A 52-week meal-test study showed improved β-cell function (insulin secretion measured as suprabasal C-peptide area under the curve divided by glucose area under the curve during standardised meal) at 12 weeks in patients who had vildagliptin added to metformin compared with metformin; this improvement was maintained over 52 weeks. 53 In another study, improved secretory tone was observed, whereby treatment increased the insulin secretory rate at any given glucose level compared with placebo. 54 The DDP-4 inhibitors appear to have side effect profiles similar to placebo 12 (see Table 2 ) and are not associated with any marked risk of hypoglycaemia as monotherapy. For example, in trials hypoglycaemia in vildagliptin-treated patients has been mild and infrequent, with rates similar to those observed with rosiglitazone (one event in each group over six months) 51 and metformin (<1% of patients over one year); 48 in an add-on study with insulin, vildagliptin treatment was associated with a decrease in the frequency and severity of hypoglycaemia compared with ongoing insulin treatment as monotherapy. 55 The DPP-4 inhibitors generally appear to be weight-neutral, 12, 46, 49, 51 although some significant reductions in bodyweight have been observed in comparative studies. For example, vildagliptin produced a 0.3kg reduction in weight compared with a 1.6kg increase with rosiglitazone; 51 among obese patients, vildagliptin was associated with a 1.1kg decrease and rosiglitazone with a 1.7kg increase. Similarly, a 52-week study in metformin-treated patients with inadequate glycaemic control showed that sitagliptin was associated with a 1.5kg decrease compared with a 1.1kg increase with glipizide. 12 Conversely, a recent 24-week study with sitagliptin in patients who had inadequate glycaemic control while on glimepiride alone or in combination with metformin found that sitagliptin add-on therapy was associated with a modest but statistically significant bodyweight increase in the entire patient cohort compared with placebo. 56 Other potential benefits of these medications are suggested by a significant reduction in GI side effects with the addition of vildagliptin to metformin, compared with ongoing metformin treatment as monotherapy. 49 The findings with oral DPP-4 inhibitors are promising. Although they appear to lack the consistently significant reduction in bodyweight associated with GLP-1 mimetics, the weight neutrality of these agents together with the absence of a need for injection, the apparent absence of significant GI adverse effects and the low risk of hypoglycaemia suggest utility particularly, although not exclusively, in obese patients. If experience in clinical practice substantiates the benefits suggested in these data, clinicians will have an exciting new option for obese patients with type 2 diabetes. The RIO-Diabetes trial compared rimonabant 5mg or 20mg with placebo for one year in more than 1,000 overweight or obese patients with type 2 diabetes who were receiving metformin (~65%) or SU (~35%). 60 The 20mg dose produced a weight reduction of 5.3kg and reduced HbA 1c by 0.6%. At this dose, a significantly greater proportion of patients with metabolic syndrome at baseline no longer met the criteria for metabolic syndrome at one year (although there was no significant difference between rimonabant and placebo with regard to proportion of patients developing metabolic syndrome during the study).
Anti-obesity Drugs -Rimonabant
Discontinuation rates were high in both rimonabant and placebo groups in all of the RIO trials, a finding that has been observed in some other anti-obesity drug trials. Although discontinuation rates were similar in all patient groups in RIO-Diabetes (see Table 3 ), discontinuation due to adverse events was more frequent in patients receiving rimonabant 20mg (15%) compared with placebo (5%). The most frequent reasons for discontinuation in the 20mg group were depressed mood disorders (11 patients, 3%), nausea (five patients, 1.5%) and dizziness (three patients, 0.9%). There is concern over the frequency of depression and depressed mood disorders observed in rimonabant-treated patients; monitoring for such effects is prudent, and additional study and experience are necessary to quantify any risks associated with these effects.
Conclusions
Obesity is a major -and modifiable -contributor to an alarming increase in type 2 diabetes worldwide. Overweight and obese patients should be encouraged to start and maintain a diet and exercise programme to lose weight; this should help in moving towards glycaemic goals and improving other metabolic risk factors. Unfortunately, although lifestyle interventions can be effective in achieving metabolic control, patients find it very difficult to maintain lifestyle changes.
The recent consensus statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommends initial treatment with lifestyle intervention and metforminwhere safe and tolerated -for all patients with type 2 diabetes, whether obese or not. The statement also emphasises the need for rapid addition of complementary medications or changes in regimens to promptly achieve and maintain glycaemia at levels as close to normal as possible. 18 When considering treatment of overweight and obese patients with type 2 diabetes, practitioners must remain aware of the potential for weight gain that is associated with many antidiabetic medications. Avoiding iatrogenic weight gain is a first step towards improved metabolic control
